Persistent AR signaling Stress response pathways Signaling pathways Developmental pathways AR, N-Terminal AR, co-factors LSD-1 and BF3 Hsp27, CLU, autophagy, Hsp90, p38 MAPK PI3K/Akt, MAPK, JNK, NF-κB, CCL2, MET, src…
Castrate-resistant a prostate carcinoma with at least 1 of the following: C1. Histologic evidence of small-cell prostate carcinoma (pure or mixed) C2. Exclusively visceral metastases C3. Radiographically predominant lytic bone…
Fig. 13.1 A pharmacologic audit trail for clinical trial design. Solid boxes contain the conceptualized trial framework; dashed boxes demonstrate the example of a new therapy targeting androgen receptor (AR)…
Fig. 8.1 Proposed model of taxane mechanism of action in prostate cancer. AR associates with microtubules and translocates to the nucleus via the motor protein dynein. Taxanes inhibit depolymerization of…
© Springer Science+Business Media New York 2014Fred Saad and Mario A. Eisenberger (eds.)Management of Castration Resistant Prostate CancerCurrent Clinical Urology10.1007/978-1-4939-1176-9_23 23. Evidence-Based Therapeutic Approaches for mCRPC Patients: Rational Sequence of Standard Treatment Options and Design…
© Springer Science+Business Media New York 2014Fred Saad and Mario A. Eisenberger (eds.)Management of Castration Resistant Prostate CancerCurrent Clinical Urology10.1007/978-1-4939-1176-9_14 14. Defining Clinical Endpoints in Castration-Resistant Prostate Cancer Jorge A. Garcia1, 2 and Robert Dreicer1, 2 (1) Department…
Fig. 7.1 Schema showing mechanism of action of CYP 17 and CYP 17 Inhibitor abiraterone acetate (AA). Note that upon inhibition of CYP 17 the mineralocorticoid path can be activated,…
Targeted treatment combined with docetaxel Phase I docetaxel combination trial in CRPC, N Any unexpected safety signals? Pharmacodynamic studies Phase II docetaxel-combination trial in CRPC design (N) Statistical plan Primary…
Fig. 15.1 TGF-β transforming growth factor-β; HGF hepatocyte growth factor; VEGF vascular endothelial growth factor; PLGF placental growth factor; Ang angiopoietin; PDGF platelet-derived growth factor; FGF fibroblast growth factor Although…
Fig. 19.1 Schematic examples of HGF/MET and/or VEGF/VEGFR inhibitors mechanism of action. VEGFR vascular endothelial growth factor receptor, PDGFR platelet-derived growth factor receptor, HGF hepatocyte growth factor, FLT3 FMS-like tyrosine…
